Classification
- Anatomical main groupLAntineoplastic and immunomodulating agents
- Therapeutic subgroupL01Antineoplastic agents
- Pharmacological subgroupL01E
- Chemical subgroupL01EX
- Chemical substanceL01EX12Larotrectinib
Where it is registered
Each register and historical list with its number of registrations and a few of them.
Spain
AEMPS · 4 registrations
- Vitrakvi 100 MG Capsulas Duras122,9 mg · cápsula dura · Bayer Ag
- VITRAKVI 20 MG/ML SOLUCION ORAL, 2 frascos de 50 ml24,6 mg/ml · solución oral · Bayer Ag
- Vitrakvi 25 MG Capsulas Duras30,7 mg · cápsula dura · Bayer Ag
- VITRAKVI 20 MG/ML SOLUCION ORAL, 1 frasco de 100 ml24,6 mg/ml · solución oral · Bayer Ag
Canada
Health Canada · 3 registrations
At a glance
- ATC code
- L01EX12
- Registers
- 9
- Historical lists
- 1
- Registrations
- 25
- With their own page
- 21
- Companies
- 10
All medicines with Larotrectinib
Human medicines from every register that match Larotrectinib by substance or by name, a page at a time, so the count can differ from the registrations above. Strengths and packs are on each medicine’s page.
25 search results
| Medicine | Register | Strength | Form | Status | Holder |
|---|---|---|---|---|---|
| Vitrakvi | United States | 100MG BASE, 25MG BASE | capsule | Marketed | Bayer Hlthcare |
| Vitrakvi | United States | 20MG BASE/ML | solution | Marketed | Bayer Healthcare |
| Vitrakvi | European Union | Authorised | Bayer AG | ||
| Vitrakvi 100 MG Capsulas Duras | Spain | 122,9 mg | cápsula dura | Marketed | Bayer Ag |
| VITRAKVI 20 MG/ML SOLUCION ORAL, 2 frascos de 50 ml | Spain | 24,6 mg/ml | solución oral | Marketed | Bayer Ag |
| Vitrakvi 25 MG Capsulas Duras | Spain | 30,7 mg | cápsula dura | Marketed | Bayer Ag |
| Vitrakvi 100 mg, harde capsules | Netherlands | Capsule, hard | Authorised | Bayer AG | |
| Vitrakvi 20 mg/ml, drank | Netherlands | Drank | Authorised | Bayer AG | |
| Vitrakvi 25 mg, harde capsules | Netherlands | Capsule, hard | Authorised | Bayer AG | |
| Vitrakvi | Canada | 100 MG | Capsule | Marketed | Bayer INC |
| Vitrakvi | Canada | 25 MG | Capsule | Marketed | Bayer INC |
| Vitrakvi | Canada | 20 MG / ML | Solution | Marketed | Bayer INC |
| Vitrakvi | Brazil | Authorised | Bayer S.A. | ||
| Vitrakvi | Brazil | Authorised | Bayer S.A. | ||
| VITRAKVI 100mg capsule | Taiwan | 膠囊劑 | Authorised | 台灣拜耳股份有限公司 | |
| VITRAKVI 20mg/ml oral solution | Taiwan | 口服液劑 | Authorised | 台灣拜耳股份有限公司 | |
| VITRAKVI 25mg capsule | Taiwan | 膠囊劑 | Authorised | 台灣拜耳股份有限公司 | |
| Vitrakvi Hard Capsule 100MG | Singapore | 100mg | capsule | Authorised | Bayer (South East Asia) Pte LTD |
| Vitrakvi Hard Capsule 25MG | Singapore | 25mg | capsule | Authorised | Bayer (South East Asia) Pte LTD |
| Vitrakvi Oral Solution 20MG/ML | Singapore | 20 mg/ml | solution | Authorised | Bayer (South East Asia) Pte LTD |
| Vitrakvi | Croatia | Marketed | |||
| Vitrakvi | Saudi Arabia | Authorised | Penn Pharmaceutical Services Ltd | ||
| Vitrakvi | Saudi Arabia | Authorised | Next Pharma | ||
| Vitrakvi | Saudi Arabia | Authorised | Penn Pharmaceutical Services Ltd | ||
| VITRAKVI 20 MG/ML SOLUCION ORAL, 1 frasco de 100 ml | Spain | 24,6 mg/ml | solución oral | Withdrawn | Bayer Ag |